220 related articles for article (PubMed ID: 12001455)
1. [Will genes become an engine to the industry?].
Nylund S; Sibakov M
Duodecim; 2000; 116(16):1763-8. PubMed ID: 12001455
[No Abstract] [Full Text] [Related]
2. The end of the beginning for genomic medicine.
Bailey D; Zanders E; Dean P
Nat Biotechnol; 2001 Mar; 19(3):207-9. PubMed ID: 11231543
[No Abstract] [Full Text] [Related]
3. Patent protection for protein structure analysis.
Shimbo I; Nakajima R; Yokoyama S; Sumikura K
Nat Biotechnol; 2004 Jan; 22(1):109-12. PubMed ID: 14704710
[TBL] [Abstract][Full Text] [Related]
4. Connecting genes, drugs and diseases.
Weinstein JN; Pommier Y
Nat Biotechnol; 2006 Nov; 24(11):1365-6. PubMed ID: 17093484
[No Abstract] [Full Text] [Related]
5. Biotech round the world: focus on Canada.
Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
[No Abstract] [Full Text] [Related]
6. Prescription for an ailing pharmaceutical industry.
Demain AL
Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
[No Abstract] [Full Text] [Related]
7. What's fueling the biotech engine?
Aggarwal S
Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
[No Abstract] [Full Text] [Related]
8. Little biotech on the prairie.
Wolfson W
Chem Biol; 2007 Sep; 14(9):969-71. PubMed ID: 17884626
[No Abstract] [Full Text] [Related]
9. Aurora throws light on Vertex's aspirations.
Fletcher L
Nat Biotechnol; 2001 Jun; 19(6):496. PubMed ID: 11385416
[No Abstract] [Full Text] [Related]
10. Biotech boom.
Jayaraman KS
Nature; 2005 Jul; 436(7050):480-3. PubMed ID: 16049469
[No Abstract] [Full Text] [Related]
11. Deal watch: Trends in platform technology deal-making.
Walker J; Jacob J
Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395
[No Abstract] [Full Text] [Related]
12. Unlocking the money-making potential of RNAi.
Howard K
Nat Biotechnol; 2003 Dec; 21(12):1441-6. PubMed ID: 14647324
[No Abstract] [Full Text] [Related]
13. How will biotechnology fare in pharma's big plan?
Nat Biotechnol; 1996 Nov; 14(11):1515. PubMed ID: 9634811
[No Abstract] [Full Text] [Related]
14. Screening for drug discovery: the leading question.
Smith A
Nature; 2002 Jul; 418(6896):453-9. PubMed ID: 12140563
[No Abstract] [Full Text] [Related]
15. Five technologies to lead the biotek.
Lubner GC
Boll Chim Farm; 2004 Jun; 143(5):194. PubMed ID: 15360106
[No Abstract] [Full Text] [Related]
16. Rediscovering plant-based drugs.
Littleton J; Falcone D; Davies HM
Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
[No Abstract] [Full Text] [Related]
17. Differentiating genomics companies.
James R
Nat Biotechnol; 2000 Feb; 18(2):153-5. PubMed ID: 10657119
[TBL] [Abstract][Full Text] [Related]
18. Genomics joint venture 2.
Davies MJ
Trends Biotechnol; 2001 May; 19(5):163. PubMed ID: 11301124
[No Abstract] [Full Text] [Related]
19. HGS drug flop latest genomics setback.
Reid B
Nat Biotechnol; 2002 Jun; 20(6):533. PubMed ID: 12042841
[No Abstract] [Full Text] [Related]
20. The impact of bacteriophage genomics.
McGrath S; Fitzgerald GF; van Sinderen D
Curr Opin Biotechnol; 2004 Apr; 15(2):94-9. PubMed ID: 15081045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
